ClinicalTrials.gg
CompletedNCT05725330Updated Nov 12, 2026

The Effect of Gamification on Patients With Type 2 Diabetes

An interventional study of Gamification and education with mobile game application in Gamification, Type 2 Diabetes and Self-management, sponsored by Sakarya University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Sakarya University · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 12, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey — 61 open to participants now, 71 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Turkey.

Enrollment
148th of 266
88 · median 100
Started
2024
with 30 others
No phase
150 of 342
33 open now
Registered
182nd of 342
by date

Among the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, this one is the 148th largest by enrollment of the 266 interventional ones that give a count, is one of 31 that started in 2024, is one of 150 with no phase, and was the 182nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

61 of the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, or all of them as a file.
02

Study summary

Diabetes is a broad-spectrum metabolic disorder that causes a defect in the organism's carbohydrate, fat, and protein metabolism processes due to insulin deficiency or impaired insulin effect. Diabetes requires continuous medical care and causes chronic, severe mortality and morbidity. More than 90% of all people with diabetes worldwide suffer from Type 2 DM. Diabetes self-management includes self-monitoring of blood glucose levels, knowing and managing the symptoms of hypoglycemia and hyperglycemia, adherence to diet, physical exercise, and diabetic foot care. Considering the high prevalent and undesirable consequences of diabetes in the world, it is necessary to benefit from new educational technologies and tools. One of these technologies is gamification, which increases the quality of education as an effective educational tool, creates motivation and enthusiasm, and develops a sense of competition in the target audience. This study plans to develop a game that will include virtual coaching to increase the self-management and glycemic control of patients with type 2 diabetes.

Read the detailed description

The research will be carried out in two stages. In Stage 1, the game will be developed; The developed game's effectiveness will be evaluated in the 2nd stage by testing it. The game's content will include healthy nutrition, exercise, foot care, insulin use, and hypoglycemia management. When the games are completed, the virtual coach will step in, and the participants will be given motivational feedback. The game developed will be evaluated by the patients in the second stage with a two-week pilot period. It will be updated according to the feedback received. The final version of the game will be passed forward to the implementation phase. Individuals who are willing to participate in the study coming to Prof. Dr. Cemil Tascioglu City Hospital Diabetes Polyclinic will be randomly assigned to the intervention and control groups. A total of 88 patients (44 controls - 44 experiments) are planned to be recruited. In the first interview with the individuals in the intervention group, Within the scope of the pretest, the "Personal Information Form," "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" will be used for evaluation. Outpatient appointment dates of the 12th week of the intervention program, "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" forms will be used with patients for the final evaluation within the scope of the posttest.

In the first meeting with the individuals in the control group, explanations about the research will be made. After their written consent is obtained at the first interview and within the scope of the pretest, the "Personal Information Form," "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" will be used for evaluation. At the end of the 12th week of the study, when they come in for their outpatient clinic appointments, as a part of the posttest, "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" forms will be used for the final evaluation.

03

Conditions studied

  • Gamification
  • Type 2 Diabetes
  • Self-management
  • Digital Health
  • Mobile Application
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Two years or more with a diagnosis of Type 2 DM
  • Patients using Insulin or Insulin and Oral Antidiabetic
  • No sensory loss, such as vision and hearing loss,
  • Having internet access and being able to use it,
  • Ability to use a mobile phone with an Android or IOS (iPhone OS) operating system
  • Patients who agreed to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with Type 1 DM and Gestational DM.
  • Visual and auditory loss,
  • Individuals without internet access
  • Unable to communicate
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Intervention Group

    Application of data collection forms for the initial evaluation. Teaching the use of mobile games, monitoring the use of mobile games in the experimental group by the researcher for 12 weeks, and applying data collection forms to the patients in the 12th week.

    Other: Gamification and education with mobile game application

  • No intervention
    Control Group

    Application of data collection forms for the initial evaluation. Application of data collection forms to the patients in the 12th week. No intervention will be made to the patients in the control group other than the routine education given in the diabetes outpatient clinic.

Interventions

  • OtherGamification and education with mobile game application

    This study aimed to provide self-care management by playing mobile games to patients with type 2 diabetes.

06

What researchers measure

Primary outcomes

  1. self-management scale

    Determining whether or not the disease self-management scale scores in patients with Type 2 DM using the developed mobile game application increased at the end of the 12 weeks period. A minimum of 0 and a maximum of 10 points are obtained on the scale. If an item is skipped, it is evaluated as -3 points. Diabetes self-management increases as the score get closer to 10.

    Time frame: Change between the first day and the 12- week of the study

Secondary outcomes

  1. glycemic control (HbA1c)

    The effect that the mobile game application developed imposes on glycemic control in patients with Type 2 DM at 12 weeks compared to baseline. The effect of the patient's HbA1c tests on the 12th week compared to the baseline. Blood test (HbA1c) will be performed during the outpatient follow-up at the first and 12th weeks.

    Time frame: Change between day one and week 12 of the study

  2. anthropometric measurements (Body Mass Index)

    The effects on anthropometric measurements in patients with Type 2 DM using the mobile game application developed compared to baseline at week 12. The effect on the patient's Body Mass Index compared to baseline at week 12. The researcher will measure it. Body Mass Index is calculated by dividing the person's weight in kilograms by the square of the person's height in meters (kg/m²).

    Time frame: The change between the first day and the 12th week of the study

07

Study locations

1 site
  • Pelin ILHAN
    Istanbul, Sisli 34360, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Mar 2025, 8 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 8 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Feb 2023 → Jun 2024, primary completion Sep 2023 → Mar 2025 and completion Dec 2023 → Mar 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2022
First posted
Feb 13, 2023
StartActual
Jun 25, 2024was Feb 2023
Primary completionActual
Mar 15, 2025was Sep 2023
CompletionActual
Mar 15, 2025was Dec 2023
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 12, 2026
Start date
Feb 25, 2023→Jun 25, 2024 (actual)
Nov 12, 2026
Primary completion
Sep 17, 2023→Mar 15, 2025 (actual)
Nov 12, 2026
Study completion
Dec 30, 2023→Mar 15, 2025 (actual)
Nov 12, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameself-management scaleChange between the first day and the sixth week of the study → Change between the first day and the 12- week of the study
  • Descriptionself-management scale: how it is measured was reworded
Nov 12, 2026
Secondary outcomes
2 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameglycemic control (HbA1c)Change between day one and week 6 of the study → Change between day one and week 12 of the study
  • Time frameanthropometric measurements (Body Mass Index)The change between the first day and the sixth week of the study → The change between the first day and the 12th week of the study
  • Descriptionanthropometric measurements (Body Mass Index): how it is measured was reworded
  • Descriptionglycemic control (HbA1c): how it is measured was reworded
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Status unknown→Completed
    Start date Feb 25, 2023→Jun 25, 2024 (now actual)
    Primary completion Sep 17, 2023→Mar 15, 2025 (now actual)
    Study completion Dec 30, 2023→Mar 15, 2025 (now actual)
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameself-management scaleChange between the first day and the sixth week of the study → Change between the first day and the 12- week of the study
    • Descriptionself-management scale: how it is measured was reworded
    Secondary outcomes 2 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameglycemic control (HbA1c)Change between day one and week 6 of the study → Change between day one and week 12 of the study
    • Time frameanthropometric measurements (Body Mass Index)The change between the first day and the sixth week of the study → The change between the first day and the 12th week of the study
    • Descriptionanthropometric measurements (Body Mass Index): how it is measured was reworded
    • Descriptionglycemic control (HbA1c): how it is measured was reworded
    + 5 other changes: verification date, description, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05725330
Lead sponsor
Sakarya University
Responsible party
Sponsor
First posted
Feb 13, 2023
Start date
Jun 25, 2024
Primary completion
Mar 15, 2025
Completion
Mar 15, 2025
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion